Key Insights

Highlights

Success Rate

80% trial completion

Published Results

13 trials with published results (18%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

15.1%

11 terminated out of 73 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

30%

22 trials in Phase 3/4

Results Transparency

30%

13 of 44 completed with results

Key Signals

13 with results80% success11 terminated

Data Visualizations

Phase Distribution

50Total
Not Applicable (10)
Early P 1 (1)
P 1 (8)
P 2 (9)
P 3 (9)
P 4 (13)

Trial Status

Completed44
Unknown13
Terminated11
Not Yet Recruiting4
Withdrawn1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 44 completed trials

Clinical Trials (73)

Showing 20 of 20 trials
NCT07481019Not ApplicableNot Yet Recruiting

A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology

NCT05936567Phase 2CompletedPrimary

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

NCT07428954Completed

Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care

NCT07428941Completed

Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.

NCT05496465Phase 2CompletedPrimary

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

NCT03545464Phase 3CompletedPrimary

COrticosteroids in acUte uRticAria in emerGency dEpartment

NCT07042828Phase 1Completed

To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting Conditions

NCT06702293Not ApplicableNot Yet Recruiting

Use of a Digital Psychotherapeutic App to Reduce Symptom Burden in Dermatology Patients

NCT06924840Not ApplicableNot Yet Recruiting

A Clinical Study to Assess the Safety and Effectiveness of Utixira Lotion and Utixira Tablet in Healthy Adult Human Subjects With Dry or Sensitive Skin Prone to Mild to Moderate Pruritus and Urticaria

NCT06859736Not Yet RecruitingPrimary

Survey on the Characteristics of Traditional Medicine Syndromes in Urticaria Patients At Le Van Thinh Hospital

NCT06755424Completed

GI Symptoms in Infants Fed Goat Milk-based Infant Formula

NCT00751218Phase 4CompletedPrimary

A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)

NCT00783354Phase 4CompletedPrimary

A Comparison of Aerius Continuous Treatment Versus Aerius PRN for Chronic Idiopathic Urticaria (Study P03147)

NCT00751166Phase 4TerminatedPrimary

A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)

NCT01916967Phase 3CompletedPrimary

An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)

NCT06210698Unknown

Angioedema Biomarker Research Study

NCT01371877Not ApplicableCompletedPrimary

The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment

NCT05330637Unknown

Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.

NCT05497596Not ApplicableUnknownPrimary

The Association Between Human Microbiome and Vitamin D in Chronic Urticaria

NCT00876369CompletedPrimary

Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema

Scroll to load more

Research Network

Activity Timeline